Avila Therapeutics™ is pioneering a method to generate and develop new medicines that achieve ‘protein silencing’ based on the proprietary Avilomics™ platform. These medicines, called covalent drugs, strongly and resiliently bond to disease-causing proteins, resulting in therapies that are highly effective against a broad spectrum of human diseases. The covalent bonding mechanism of Avila’s drugs has the unique property of effectively ‘silencing’ disease-causing proteins by establishing a strong and enduring ‘bond’ – exceeding the more temporary ‘binding’ of conventional drugs – to completely shut down the activity of and silence a disease-causing protein. Avila’s covalent drugs have exceptional therapeutic benefits because they are highly targeted, are effective against mutations and have a long duration of action.